Equity Profile

CAI

Caris Life Sciences, Inc.

Health CareBiotechnology$4.7B

May7Thu

Post-Earnings Recap

ReportedQ1-2026After Close4:05 PM EDT

Caris Life Sciences, Inc. Meets EPS Expectations, Stock Up 3.71%

Metric	Actual	Expected	Surprise
EPS	$0.00	N/A	+100.00%
Revenue	—	N/A	—

management commentary, guidance changes, and full analysis available with Pro.

Caris Life Sciences, Inc. Meets EPS Expectations, Stock Up 3.71%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$0.00	N/A	+100.00%
Revenue	—	N/A	—

Management Commentary

Tone: Unknown

No transcript is on record, and the analysis is based solely on numerical results.

What It Means

Caris Life Sciences reported an EPS of $0.00, which met expectations, resulting in a 3.71% increase in stock price. However, there was no revenue reported, and no guidance was provided for future performance. The stock reaction suggests that investors may have found the EPS result encouraging, despite the lack of additional financial details.

Company Snapshot

Caris Life Sciences, Inc. is a biotechnology company focused on precision medicine....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of a company's profitability and performance. Investors will be keen to see if Caris can continue its trend of beating EPS estimates.

N/A

Revenue Growth

Revenue growth is essential for assessing the company's ability to expand its market share and sustain operations.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Caris Life Sciences, Inc. is a biotechnology company focused on precision medicine. They provide advanced genomic testing services that help healthcare providers make more informed treatment decisions. As part of the health care sector, their work is critical in the evolving landscape of personalized medicine.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+541.94%

Avg Stock Reaction

+1.24%

Last Quarter Recap

In the last quarter, Caris Life Sciences reported a significant EPS surprise of $0.28, far exceeding expectations. The stock reacted positively, gaining 5.08% the next day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for Caris Life Sciences are mixed as the company has shown a strong ability to beat EPS estimates in the past. However, there is uncertainty regarding revenue figures and future guidance.

Bull Case

The optimistic view is that Caris will continue its streak of beating EPS estimates, potentially leading to increased investor confidence and stock price appreciation.

Bear Case

On the other hand, if Caris fails to meet expectations or provides weak guidance, it could lead to a decline in stock price, reflecting investor disappointment.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q1-2026?

Given Caris's history of beating EPS estimates, the market will closely watch this figure to gauge ongoing profitability.

What are the revenue figures for this quarter?

Revenue is crucial for understanding the company's growth trajectory and market position, especially in the competitive biotech space.

Edge

What the Street Is Missing

Why consensus could be wrong

The market may underestimate Caris's ability to leverage its genomic testing services for revenue growth, especially in light of recent advancements in precision medicine.

Supporting Evidence

Caris has consistently beaten EPS estimates, indicating strong operational execution.

The options market is pricing in a larger move than historical averages, suggesting heightened expectations.

Recent trends in personalized medicine could drive demand for Caris's services beyond current projections.

Key Risk

If revenue growth exceeds expectations, it could challenge the current cautious outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it will determine if Caris can maintain its momentum or if it will face challenges.

Bull Confirmed If

An EPS of $0.30 or higher would confirm the bull case and indicate strong operational performance.

Bear Confirmed If

An EPS below $0.01 would confirm the bear case and raise concerns about the company's profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±12.66%

Historical Avg

±5.6%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±31.7% while CAI has averaged ±5.6% over the last 4 prints — setup is pricing rich.

Detail

ATM IV

3.3%

30d HV

63.9%

Calls (7K)P/C Ratio: 1.00Puts (1K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Caris beats expectations, history suggests a potential stock increase of around 6.28%, confirming strong operational health.

In-Line / Cautious

If results are in line with expectations, the stock may react cautiously, reflecting uncertainty in future growth.

Miss

A miss could lead to a decline, with historical patterns suggesting a potential drop of around 6.32%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new genomic testing services or partnerships.
2Insights into customer acquisition and retention rates.
3Management's outlook on market trends in precision medicine.
4Details on cost management and operational efficiency improvements.
5Any guidance on future earnings or revenue expectations.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

May4

BMRNReported

BioMarin Pharmaceutical Inc.

RecapView

May4

PLTRReported

Company Snapshot

Caris Life Sciences, Inc. is a biotechnology company focused on precision medicine....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of a company's profitability and performance. Investors will be keen to see if Caris can continue its trend of beating EPS estimates.

N/A

Revenue Growth

Revenue growth is essential for assessing the company's ability to expand its market share and sustain operations.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+541.94%

Avg Stock Reaction

+1.24%

Last Quarter Recap

In the last quarter, Caris Life Sciences reported a significant EPS surprise of $0.28, far exceeding expectations. The stock reacted positively, gaining 5.08% the next day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

The optimistic view is that Caris will continue its streak of beating EPS estimates, potentially leading to increased investor confidence and stock price appreciation.

Bear Case

On the other hand, if Caris fails to meet expectations or provides weak guidance, it could lead to a decline in stock price, reflecting investor disappointment.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q1-2026?

Given Caris's history of beating EPS estimates, the market will closely watch this figure to gauge ongoing profitability.

What are the revenue figures for this quarter?

Revenue is crucial for understanding the company's growth trajectory and market position, especially in the competitive biotech space.

Edge

What the Street Is Missing

Why consensus could be wrong

The market may underestimate Caris's ability to leverage its genomic testing services for revenue growth, especially in light of recent advancements in precision medicine.

Supporting Evidence

Caris has consistently beaten EPS estimates, indicating strong operational execution.

The options market is pricing in a larger move than historical averages, suggesting heightened expectations.

Recent trends in personalized medicine could drive demand for Caris's services beyond current projections.

Key Risk

If revenue growth exceeds expectations, it could challenge the current cautious outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it will determine if Caris can maintain its momentum or if it will face challenges.

Bull Confirmed If

An EPS of $0.30 or higher would confirm the bull case and indicate strong operational performance.

Bear Confirmed If

An EPS below $0.01 would confirm the bear case and raise concerns about the company's profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±12.66%

Historical Avg

±5.6%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±31.7% while CAI has averaged ±5.6% over the last 4 prints — setup is pricing rich.

Detail

ATM IV

3.3%

30d HV

63.9%

Calls (7K)P/C Ratio: 1.00Puts (1K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Caris beats expectations, history suggests a potential stock increase of around 6.28%, confirming strong operational health.

In-Line / Cautious

If results are in line with expectations, the stock may react cautiously, reflecting uncertainty in future growth.

Miss

A miss could lead to a decline, with historical patterns suggesting a potential drop of around 6.32%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new genomic testing services or partnerships.
2Insights into customer acquisition and retention rates.
3Management's outlook on market trends in precision medicine.
4Details on cost management and operational efficiency improvements.
5Any guidance on future earnings or revenue expectations.